Asahi Glass Co., Ltd. - Acquisition of CMC Biologics

Leading Japanese law firm Nishimura & Asahi has advised Asahi Glass Co., Ltd. (“AGC”) on its acquisition of CMC Biologics (“CMC”), a world-leading biologics Active Pharmaceutical Ingredients (“API”) manufacturer, for about JPY 60 billion (approx. US 511 million).

CMC is a Contract Development and Manufacturing Organization (“CDMO”), offering biological API manufacturing services with mammalian and microbial hosts. The company provides high value-added cell line construction, process development, scale-up and manufacturing of API used in drug development (pre-clinical and clinical trials) and in commercially-marketed biopharmaceutical drugs. With about 530 employees, CMC operates on a global scale with production facilities in Denmark (Copenhagen) and the US (Seattle and Berkeley). 

AGC is a Japanese world-leading manufacturer of glass, chemicals and high-tech materials. Its acquisition of CMC will enable expansion of its biologics CDMO operations, complementing AGC’s current operations in Japan and Europe. 

The Nishimura & Asahi team advising AGC was led by partners Somuku Iimura, Yasutaka NishikoriTakahiko Date and Yoshiyuki Asaoka.